Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease

Otoni, Cristiane C.; Heilmann, Romy M.; García-Sancho, Mercedes; Sainz, Á.; Ackermann, Mark R.; Suchodolski, Jan S.; Steiner, Jörg M.; Jergens, Albert E.

doi:10.1111/jvim.15123

Cited by 41 publications

(73 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seropositivity for pANCA (and also pANCA titers) is higher in dogs with FRE (61%‐62%) than in those with IRE or NRE (0%‐37%) 95, 99, 100, 101. However, pANCA seropositivity is not specific for CIE and also can occur with other immune‐mediated, infectious, or neoplastic diseases 101, 102.…”

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

“…Serum calprotectin concentrations are increased in dogs with CIE,47, 94, 116 but serum calprotectin is not specific for the gastrointestinal tract and must be interpreted with caution in corticosteroid‐treated dogs 94, 95, 117, 118…”

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

“…Fecal calprotectin concentrations have been evaluated in dogs with chronic gastrointestinal inflammation50, 95, 121 and appear to serve as a useful biomarker of intestinal inflammation in dogs. Fecal calprotectin concentrations are a good surrogate marker of disease severity in dogs with CIE,50, 95, 121 with a cut‐off value of ~50 μg/g feces to identify dogs with severe clinical disease 121. Fecal calprotectin concentration also appears to have utility in predicting the response to treatment in dogs with CIE,50 and concentrations ≥15.2 μg/g distinguish partial responders or nonresponders (PR/NR) from dogs with IRE that achieve complete clinical remission (CR) with a sensitivity of 80% and a specificity of 75%.…”

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

See 3 more Smart Citations

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Heilmann

Steiner

2018

Veterinary Internal Medicne

Self Cite

108

View full text Add to dashboard Cite

Chronic inflammatory enteropathies (CIE) in dogs are a group of disorders that are characterized by chronic persistent or recurrent signs of gastrointestinal disease and histologic evidence of mucosal inflammation. These CIEs are classified as either food‐responsive, antibiotic‐responsive, or immunosuppressant‐responsive enteropathy. Patients not clinically responding to immunomodulatory treatment are grouped as nonresponsive enteropathy and dogs with intestinal protein loss as protein‐losing enteropathy. Disease‐independent clinical scoring systems were established in dogs for assessment of clinical disease severity and patient monitoring during treatment. Histopathologic and routine clinicopathologic findings are usually not able to distinguish the subgroups of CIE. Treatment trials are often lengthy and further diagnostic tests are usually at least minimally invasive. Biomarkers that can aid in defining the presence of disease, site of origin, severity of the disease process, response to treatment, or a combination of these would be clinically useful in dogs with CIE. This article summarizes the following biomarkers that have been evaluated in dogs with CIE during the last decade, and critically evaluates their potential clinical utility in dogs with CIE: functional biomarkers (cobalamin, methylmalonic acid, folate, α1‐proteinase inhibitor, immunoglobulin A), biochemical biomarkers (C‐reactive protein, perinuclear anti‐neutrophilic cytoplasmic antibodies, 3‐bromotyrosine, N‐methylhistamine, calprotectin, S100A12, soluble receptor of advanced glycation end products, cytokines and chemokines, alkaline phosphatase), microbiomic biomarkers (microbiome changes, dysbiosis index), metabolomic biomarkers (serum metabolome), genetic biomarkers (genomic markers, gene expression changes), and cellular biomarkers (regulatory T cells). In addition, important performance criteria of diagnostic tests are briefly reviewed.

show abstract

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

Section: Biomarkers In Chronic Inflammatory Enteropathies Of Dogsmentioning

confidence: 99%

See 2 more Smart Citations

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Heilmann

Steiner

2018

Veterinary Internal Medicne

Self Cite

108

View full text Add to dashboard Cite

show abstract

“…Besides applications in oncology, efforts are on the way to harness the immunosuppressive property of CAR T cell for the treatment of autoimmune diseases, such as inflammatory bowel disease (IBD) (93), thereby opening new avenues for comparative medicine and parallel drug development as the dog is a spontaneous animal disease model for IBD as well (94).…”

Section: Comparative Oncology: An Opportunity To Accelerate Parallel mentioning

confidence: 99%

CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies

Mochel

Ekker

Johannes

et al. 2019

AAPS J

Self Cite

View full text Add to dashboard Cite

The advent of the genome editing era brings forth the promise of adoptive cell transfer using engineered chimeric antigen receptor (CAR) T cells for targeted cancer therapy. CAR T cell immunotherapy is probably one of the most encouraging developments for the treatment of hematological malignancies. In 2017, two CAR T cell therapies were approved by the US Food and Drug Administration: one for the treatment of pediatric acute lymphoblastic leukemia (ALL) and the other for adult patients with advanced lymphomas. However, despite significant progress in the area, CAR T cell therapy is still in its early days and faces significant challenges, including the complexity and costs associated with the technology. B cell lymphoma is the most common hematopoietic cancer in dogs, with an incidence approaching 0.1% and a total of 20-100 cases per 100,000 individuals. It is a widely accepted naturally occurring model for human non-Hodgkin's lymphoma. Current treatment is with combination chemotherapy protocols, which prolong life for less than a year in canines and are associated with severe dose-limiting side effects, such as gastrointestinal and bone marrow toxicity. To date, one canine study generated CAR T cells by transfection of mRNA for CAR domain expression. While this was shown to provide a transient anti-tumor activity, results were modest, indicating that stable, genomic integration of CAR modules is required in order to achieve lasting therapeutic benefit. This commentary summarizes the current state of knowledge on CAR T cell immunotherapy in human medicine and its potential applications in animal health, while discussing the potential of the canine model as a translational system for immuno-oncology research.

show abstract

Serum/Faecal S100A12, CRP and lactoferrin can be used to distinguish ınfectious and non‐ınfectious canine diarrhoea

Maden,

Gülersoy

2023

Veterinary Medicine & Sci

View full text Add to dashboard Cite

ObjectivesThis study aimed to evaluate the diagnostic efficacies of selected inflammatory and intestinal biomarkers in cases of infectious and non‐infectious diarrhoea in dogs.MethodsA total of 60 dogs, 12 healthy (Control Group) and 48 with diarrhoea were used. Viral, Bacterial, Parasitic (infectious) and Nutritional diarrhoea (non‐infectious) subgroups (n: 12) were formed according to the aetiology, on the basis of clinical and laboratory examinations. Selected inflammatory and intestinal biomarkers (Calgranulin, S100A12; Lactoferrin, LCTF; C‐reactive protein, CRP) were measured both in serum and faecal samples.ResultsCompared to the Control and Nutritional Diarrhoea groups, the infectious diarrhoea groups had higher serum S100A12, LCTF, CRP, blood urea nitrogen, creatinine (CR), alanine transaminase and alkaline phosphatase, and lower glucose (GLU), sodium (Na) and potassium (K) concentrations (p < 0.05); Viral and Parasitic Diarrhoea groups had lower serum albumin (ALB) and total protein (TP) concentrations (p < 0.05). Faecal S100A12, LCTF and CRP concentrations were higher in infectious diarrhoea groups compared to the Control and Nutritional Diarrhoea groups (p < 0.05). Faecal LCTF and CRP concentrations were higher in the Bacterial Diarrhoea group than in the Viral and Parasitic Diarrhoea groups (p < 0.05).Clinical significanceIt was determined that serum (area under curve, AUC: 0.842 and 0.956) and faecal (AUC: 0.975 and 0.786) S100A12 and CRP concentrations in viral diarrhoea; serum (AUC: 0.956) and faecal (AUC: 0.992) LCTF concentrations in bacterial diarrhoea have diagnostic values in the diagnosis of the presence of intestinal inflammation and damage and can be used in the differential diagnosis of infectious and non‐infectious diarrhoea.

show abstract

Serologic and fecal markers to predict response to induction therapy in dogs with idiopathic inflammatory bowel disease

Cited by 41 publications

References 53 publications

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

Clinical utility of currently available biomarkers in inflammatory enteropathies of dogs

CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies

Serum/Faecal S100A12, CRP and lactoferrin can be used to distinguish ınfectious and non‐ınfectious canine diarrhoea

Contact Info

Product

Resources

About